Targets › EBOV
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Jun 2027.
Open in Phaseline: the race on EBOV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Epicentre | ERVEBO Live attenuated Zaire ebolavirus vaccine | EBOV | Phase 4 | Ebola | Jun 2027 |
Ebola (1)
other (1)
Epicentre (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.